|
1. 行政院衛生署國民健康局台灣癌症登記小組: 癌症侵襲癌發生 率及死亡率. 民國94 年. 2. Zawacki KL, Phillips M: Cancer genetics and women's health. J Obstet Gynecol Neonatal Nurs 2002, 31:208-216. 3. Lefevre JH, Parc Y, Svrcek M, Kerneis S, Colas C, Shields C, Flejou JF, Parc R, Tiret E: APC, MYH, and the correlation genotype-phenotype in colorectal polyposis. Ann Surg Oncol 2009, 16:871-877. 4. Smith R, Cokkinides V, Brawley O: - Cancer screening in the United States, 2009: A review of current American Cancer. - CA Cancer J Clin 2009 Jan-Feb;59(1):27-41:- 27-41. 5. Mita AC, Mita MM, Nawrocki ST, Giles FJ: Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008, 14:5000-5005. 6. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun M: - Cancer statistics, 2007. - CA Cancer J Clin 2007 Jan-Feb;57(1):43-66:- 43-66. 7. Gold P, Freedman SO: Demonstration of Tumor-Specific Antigens in Human Colonic Carcinomata by Immunological Tolerance and Absorption Techniques. J Exp Med 1965, 121:439-462. 8. Conaghan P, Ashraf S, Tytherleigh M, Wilding J, Tchilian E, Bicknell D, Mortensen NJ, Bodmer W: Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen. Br J Cancer 2008, 98:1217-1225. 9. Liu W, Wang P, Li Z, Xu W, Dai L, Wang K, Zhang J: - Evaluation of tumour-associated antigen (TAA) miniarray in immunodiagnosis of. - Scand J Immunol 2009 Jan;69(1):57-63:- 57-63. 10. Ladd J, Lu H, Taylor AD, Goodell V, Disis ML, Jiang S: Direct detection of carcinoembryonic antigen autoantibodies in clinical human serum samples using a surface plasmon resonance sensor. Colloids Surf B Biointerfaces 2009, 70:1-6. 11. Hamilton SR: Targeted therapy of cancer: new roles for pathologists in colorectal cancer. Mod Pathol 2008, 21 Suppl 2:S23-30. 12. Gmeiner WH: Novel chemical strategies for thymidylate synthase inhibition. Curr Med Chem 2005, 12:191-202. 13. Hamilton S: - Targeted therapy of cancer: new roles for pathologists in colorectal cancer. - Mod Pathol 2008 May;21 Suppl 2:S23-30:T - ppublish. 14. Arkenau HT, Brunetto AT, Barriuso J, Olmos D, Eaton D, de Bono J, Judson I, Kaye S: Clinical Benefit of New Targeted Agents in Phase I Trials in Patients with Advanced Colorectal Cancer. Oncology 2009, 76:151-156. 15. Connell JO, Maggard M, Ko C: - Colon cancer survival rates with the new American Joint Committee on Cancer sixth. - J Natl Cancer Inst 2004 Oct 6;96(19):1420-5:- 1420-1425. 16. Caldas H, Jiang Y, Holloway MP, Fangusaro J, Mahotka C, Conway EM, Altura RA: Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 2005, 24:1994-2007. 17. Gupta AK, Brenner DE, Turgeon DK: Early detection of colon cancer: new tests on the horizon. Mol Diagn Ther 2008, 12:77-85. 18. Sajid KM, Parveen R, Durr e S, Chaouachi K, Naeem A, Mahmood R, Shamim R: Carcinoembryonic antigen (CEA) levels in hookah smokers, cigarette smokers and non-smokers. J Pak Med Assoc 2007, 57:595-599. 19. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C, Topolcan O: Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007, 43:1348-1360. 20. Casiano CA, Mediavilla-Varela M, Tan EM: Tumor-associated antigen arrays for the serological diagnosis of cancer. Mol Cell Proteomics 2006, 5:1745-1759. 21. Megliorino R, Shi FD, Peng XX, Wang X, Chan EK, Tan EM, Zhang JY: Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detect Prev 2005, 29:241-248. 22. Gordan JD, Vonderheide RH: Universal tumor antigens as targets for immunotherapy. Cytotherapy 2002, 4:317-327. 23. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC, Jr.: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006, 24:5313-5327. 24. Cao L, Wang Z, Yang X, Xie L, Yu L: The evolution of BIR domain and its containing proteins. FEBS Lett 2008, 582:3817-3822. 25. Wei Y, Fan T, Yu M: Inhibitor of apoptosis proteins and apoptosis. Acta Biochim Biophys Sin (Shanghai) 2008, 40:278-288. 26. Altieri DC: Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003, 22:8581-8589. 27. Yamamoto H, Ngan CY, Monden M: Cancer cells survive with survivin. Cancer Sci 2008, 99:1709-1714. 28. Andersen MH, Svane IM, Becker JC, Straten PT: The universal character of the tumor-associated antigen survivin. Clin Cancer Res 2007, 13:5991-5994. 29. Kennedy SM, O'Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Linehan R, Clynes M: Prognostic importance of survivin in breast cancer. Br J Cancer 2003, 88:1077-1083. 30. Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, Tanaka K, Tenjo T, Tanigawa N: Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 2001, 91:2026-2032. 31. Abd El-Hameed A: Survivin expression in colorectal adenocarcinoma using tissue microarray. J Egypt Natl Canc Inst 2005, 17:42-50. 32. Rosato A, Pivetta M, Parenti A, Iaderosa GA, Zoso A, Milan G, Mandruzzato S, Del Bianco P, Ruol A, Zaninotto G, Zanovello P: Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma. Int J Cancer 2006, 119:1717-1722. 33. Hinnis AR, Luckett JC, Walker RA: Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer 2007, 96:639-645. 34. Sohn DM, Kim SY, Baek MJ, Lim CW, Lee MH, Cho MS, Kim TY: Expression of survivin and clinical correlation in patients with breast cancer. Biomed Pharmacother 2006, 60:289-292. 35. Lu B, Gonzalez A, Massion PP, Shyr Y, Shaktour B, Carbone DP, Hallahan DE: Nuclear survivin as a biomarker for non-small-cell lung cancer. Br J Cancer 2004, 91:537-540. 36. Shariat SF, Casella R, Khoddami SM, Hernandez G, Sulser T, Gasser TC, Lerner SP: Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 2004, 171:626-630. 37. Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y: Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 2007, 109:1106-1113. 38. Wang TT, Qian XP, Liu BR: Survivin: potential role in diagnosis, prognosis and targeted therapy of gastric cancer. World J Gastroenterol 2007, 13:2784-2790. 39. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE: The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998, 17:3247-3259. 40. Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ: Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 2000, 46:645-650. 41. Rodel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R, Rodel C: Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005, 65:4881-4887. 42. Fukuda S, Pelus LM: Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 2006, 5:1087-1098. 43. Watson AJ: An overview of apoptosis and the prevention of colorectal cancer. Crit Rev Oncol Hematol 2006, 57:107-121. 44. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N: Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998, 58:5071-5074. 45. Sarela AI, Scott N, Ramsdale J, Markham AF, Guillou PJ: Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. Ann Surg Oncol 2001, 8:305-310. 46. Zhao J, Tenev T, Martins LM, Downward J, Lemoine NR: The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci 2000, 113 Pt 23:4363-4371. 47. 沈才貴: Survivin 之檢驗試劑研發及其臨床應用之研究. 長庚醫 學大學醫學生物技術研究所碩士論文2004.
|